You are here: Home » Companies » News
Business Standard

XCyton launches therapeutic decision support system

BS Reporter  |  Bangalore 

XCyton, a molecular biology company, has developed the Syndrome Evaluation System (SES) that allows for the immediate identification of multiple organisms in a specific test from a single sample that provides the clinician with an assessment of a patient.

The Syndrome Evaluation System (SES) has been announced by XCyton Diagnostics, a diagnostic product development company with a focus on molecular biology. Kiran Mazumdar Shaw, CMD of Biocon, has personally invested in XCyton.

Commercially-available conventional tests like bacterial and fungal cultures, viral cultures or immunological tests take three to seven days to identify andôor detect the illness.

Hence, it’s not of any help to the physician in taking a decision at that critical hour. With SES it is possible to have a report in just seven hours.

B V Ravi Kumar, founder CMD of XCyton Diagnostics Pvt Ltd, said, “My belief that lives can be saved and disabilities can be prevented if the diagnosis is made early during the infection led to the creation of the SES.”

Kiran Mazumdar Shaw says, “XCyton’s syndrome evaluation diagnostics is a differentiated platform that will provide a way of diagnosing critical care infections and provide treatment outcomes. This is yet another approach to personalised medicine that is a very sought after space where XCyton is an early entrant from India.”

XCyton is now backed by Fidelity Growth Partners India (FGPI) which is the India-focused private equity arm of Fidelity Worldwide Investment.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, March 18 2012. 21:49 IST
RECOMMENDED FOR YOU
.